The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

Resources from the National Institutes of Health Chemical Genomics Center include a database and a physical collection of approved drugs. Small-molecule compounds approved for use as drugs may be “repurposed” for new indications and studied to determine the mechanisms of their beneficial and adverse effects. A comprehensive collection of all small-molecule drugs approved for human use would be invaluable for systematic repurposing across human diseases, particularly for rare and neglected diseases, for which the cost and time required for development of a new chemical entity are often prohibitive. Previous efforts to build such a comprehensive collection have been limited by the complexities, redundancies, and semantic inconsistencies of drug naming within and among regulatory agencies worldwide; a lack of clear conceptualization of what constitutes a drug; and a lack of access to physical samples. We report here the creation of a definitive, complete, and nonredundant list of all approved molecular entities as a freely available electronic resource and a physical collection of small molecules amenable to high-throughput screening.

[1]  E. Gibson,et al.  The Serotonergic Appetite Suppressant Fenfluramine , 1999 .

[2]  The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection. , 1999, Advances in experimental medicine and biology.

[3]  J. Griffin Prepulsid withdrawn from UK & US markets. , 2000, Adverse drug reactions and toxicological reviews.

[4]  J. Jacobson Thalidomide: a remarkable comeback , 2000, Expert opinion on pharmacotherapy.

[5]  Griffin Jp Prepulsid withdrawn from UK & US markets. , 2000 .

[6]  Jon Glasby Ba A betrayal of trust? , 2012, Nursing older people.

[7]  Christopher P Austin,et al.  The impact of the completed human genome sequence on the development of novel therapeutics for human disease. , 2004, Annual review of medicine.

[8]  R. Dabbah,et al.  The Value of USP Public Standards for Therapeutic Products , 2004, Pharmaceutical Research.

[9]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[10]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[11]  Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model. , 2005, Retina.

[12]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[13]  M. Feinberg,et al.  Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases , 2005, Nature Medicine.

[14]  J. Lexchin Drug withdrawals from the Canadian market for safety reasons, 1963–2004 , 2005, Canadian Medical Association Journal.

[15]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. McNeil,et al.  Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity , 2006, Drug safety.

[17]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[18]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[19]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[20]  S. Colan,et al.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.

[21]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[22]  M. Blommel,et al.  Pregabalin: an antiepileptic agent useful for neuropathic pain. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  Ruili Huang,et al.  Fluorescence spectroscopic profiling of compound libraries. , 2008, Journal of medicinal chemistry.

[24]  Christopher P Austin,et al.  Characterization of chemical libraries for luciferase inhibitory activity. , 2008, Journal of medicinal chemistry.

[25]  Philip J Mease,et al.  A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. , 2008, The Journal of rheumatology.

[26]  M. Spaeth Is pregabalin a safe and effective treatment for patients with fibromyalgia? , 2008, Nature Clinical Practice Rheumatology.

[27]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[28]  S. Ōmura Ivermectin: 25 years and still going strong. , 2008, International journal of antimicrobial agents.

[29]  G J Ebrahim,et al.  Neglected tropical diseases , 2005, BMJ : British Medical Journal.

[30]  Robert J Kavlock,et al.  Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[31]  Ruili Huang,et al.  The pilot phase of the NIH Chemical Genomics Center. , 2009, Current topics in medicinal chemistry.

[32]  Christopher P Austin,et al.  Monitoring Compound Integrity With Cytochrome P450 Assays and qHTS , 2009, Journal of biomolecular screening.

[33]  Melvin E Andersen,et al.  Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[34]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[35]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[36]  Ruili Huang,et al.  Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. , 2010, Biochemical pharmacology.

[37]  王林,et al.  Office of Rare Diseases Research , 2011 .

[38]  Ruili Huang,et al.  Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.